Cytokinetics (CYTK)
NASDAQ: CYTK
· Real-Time Price · USD
31.32
1.04 (3.43%)
At close: May 29, 2025, 3:59 PM
30.50
-2.62%
After-hours: May 29, 2025, 05:20 PM EDT
3.43% (1D)
| Bid | 29.34 |
| Market Cap | 3.74B |
| Revenue (ttm) | 19.22M |
| Net Income (ttm) | -615.26M |
| EPS (ttm) | -5.29 |
| PE Ratio (ttm) | -5.92 |
| Forward PE | -6.21 |
| Analyst | Buy |
| Ask | 31.66 |
| Volume | 1,154,088 |
| Avg. Volume (20D) | 2,154,170 |
| Open | 30.54 |
| Previous Close | 30.28 |
| Day's Range | 30.05 - 31.36 |
| 52-Week Range | 29.31 - 61.38 |
| Beta | 0.81 |
About CYTK
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CYTK
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CYTK stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts4 weeks ago
-12.98%
Cytokinetics shares are trading lower after the co...
Unlock content with
Pro Subscription
3 weeks ago
+0.19%
Cytokinetics shares are trading lower after the company announced the FDA has extended the Prescription Drug User Fee Act action date for Aficamten.
